Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVR vs VVOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVR Captures Overall Composite Edge (42.0 HOLD vs 36.4 SELL), While VVOS Leads 3–2 on Growth & Valuation Pillars

AVR Overall Winner 6-Pillar Tally: AVR 2 – 3 VVOS (1 Tie) Matrix Metrics: AVR 6 – 2 VVOS

As of Nov 20, 2026, Anteris Technologies Global Corp. (AVR) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (42.0/100 HOLD vs. 36.4/100 SELL) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. AVR trades at $4.99 (N/M Forward P/E, -4880.4% operating margin) versus VVOS at $0.05 (N/M Forward P/E, -107.9% operating margin).

  • Growth vs. Quality Trade-Off: AVR earns the overall head-to-head edge with a stronger Unified Composite Score (42.0/100 HOLD vs. VVOS 36.4/100 SELL) and 1.49β · 78% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.4); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVR vs VVOS
AVR NASDAQ Head-to-Head Winner
Anteris Technologies Global Corp. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$4.99
-1.96% 1D
Market Cap $496.2M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 1.49β · 78% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 32.0 Fund 52.0 Flow 57.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.0%), weak momentum, RSI 34
RSI-14: 34.4 · SMA20: $5.75 · SMA50: $6.63
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13

6-Pillar Scorecard Institutional Category Breakdown (AVR 2 – 3 VVOS)

Columns: Metric · AVR · VVOS
1. Valuation Multiples VVOS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 120.1x 0.1x
2. Growth & Scale VVOS
Revenue Growth (YoY) +21.0% +34.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M $21M
Market Cap $496.2M $1.9M
3. Profitability & Quality AVR
Gross Margin 75.8% 61.9%
Operating Margin -4880.4% -107.9%
Net Profit Margin 0.0% -121.8%
Return on Equity (ROE) -93.3% -8585.3%
4. Balance Sheet & Cash Flow VVOS
Cash Generation (TTM) -$94M -$21M EBITDA
Cash Flow Margin N/A -99.3% EBITDA Mgn
Net Cash / Leverage $216M Net Cash -8585.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVR
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 151.1% (69th %ile) N/A (N/A)
Put/Call OI Skew 4.63x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVR (6) vs VVOS (2)
Institutional Metric AVR VVOS Criterion Row Edge
Market Capitalization
Scale
$496.2M $1.9M Larger Scale AVR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+21.0% +34.9% Higher Growth VVOS
Operating Margin (TTM)
Profitability
-4880.4% -107.9% Higher Margin VVOS
Net Profit Margin
Profitability
0.0% -121.8% Higher Margin AVR
Return on Equity (ROE)
Capital Efficiency
-93.3% -8585.3% Higher ROE AVR
52-Week Range Position
Momentum
22% ($3–$11) 0% ($0–$3) Stronger Trend AVR
Beta / 30D Volatility
Risk Regime
1.49β · 78% Vol 1.70β · 111% Vol Lower Realized Risk AVR
Unified Institutional Score
Composite Signal
42.0 / 100 (HOLD) 36.4 / 100 (SELL) Higher Composite AVR
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 61.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 120.1x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$94M ($216M Net Cash) -$21M EBITDA (-8585.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVR +42.42 pp
AVR: -16.83% · VVOS: -59.25%
3M Horizon AVR +37.19 pp
AVR: -43.3% · VVOS: -80.49%
6M Horizon AVR +43.02 pp
AVR: -48.13% · VVOS: -91.15%
1Y Horizon AVR +144.47 pp
AVR: +46.76% · VVOS: -97.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AVR Revenue VVOS Revenue AVR Op. Margin VVOS Op. Margin Margin Leader
FY2019 N/A $10M N/A -92.8% VVOS
FY2020 N/A $10M N/A -92.1% VVOS
FY2021 N/A $20M N/A -120.7% VVOS
FY2022 N/A $20M N/A -156.2% VVOS
FY2023 N/A $10M N/A -125.3% VVOS
FY2024 $0M $20M -2899.4% -74.3% VVOS
FY2025 $0M $20M -4908.2% -114.1% VVOS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVR BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 151.1%
IV Percentile 69th %ile
Put/Call OI Skew 4.63x (Put-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact AVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $496.2M market capitalization and -4880.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVR vs VVOS Key Questions & Quantitative Answers

As of Nov 20, 2026, Anteris Technologies Global Corp. (AVR) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (42.0/100 HOLD vs. 36.4/100 SELL) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. AVR trades at $4.99 (N/M Forward P/E, -4880.4% operating margin) versus VVOS at $0.05 (N/M Forward P/E, -107.9% operating margin). Growth vs. Quality Trade-Off: AVR earns the overall head-to-head edge with a stronger Unified Composite Score (42.0/100 HOLD vs. VVOS 36.4/100 SELL) and 1.49β · 78% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.4); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VVOS leads the Growth & Scale pillar: AVR posts +21.0% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (75.8% gross margin, -4880.4% operating margin), compared with VVOS at +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), AVR cumulative revenue shifted N/A while VVOS shifted +100.0%. In operating R&D and SG&A reinvestment, AVR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VVOS.

VVOS screens cheaper on headline valuation multiples. AVR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 120.1x EV/Revenue (unreported FCF margin), whereas VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVR (-93.3% ROE) versus VVOS (-8585.3% ROE) capital efficiency.

In options market volatility and institutional positioning, AVR carries 151.1% implied volatility (69th %ile, Elevated (60th–80th %ile)), a 4.63x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.49β · 78% Vol realized risk). By comparison, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.